Impact of Dabigatran Treatment on Rotation Thromboelastometry

Autor: Jana Zolkova, Juraj Sokol, Frantisek Nehaj, Jela Ivankova, Marian Mokan, Jan Stasko, Ludmila Linekova, M. Mokan, Lenka Lisa
Jazyk: angličtina
Rok vydání: 2021
Předmět:
Male
medicine.medical_specialty
lcsh:Diseases of the circulatory (Cardiovascular) system
medicine.drug_class
Population
rotation thromboelastometry
030204 cardiovascular system & hematology
Gastroenterology
Antithrombins
Dabigatran
03 medical and health sciences
0302 clinical medicine
Predictive Value of Tests
Internal medicine
Atrial Fibrillation
medicine
Humans
030212 general & internal medicine
education
Blood Coagulation
Whole blood
Aged
Aged
80 and over
education.field_of_study
business.industry
Anticoagulant
Reproducibility of Results
Atrial fibrillation
Hematology
General Medicine
Middle Aged
medicine.disease
Thrombelastography
Thromboelastometry
monitoring
Treatment Outcome
Clotting time
Point-of-Care Testing
lcsh:RC666-701
Hemostasis
hemostasis
Female
Original Article
Drug Monitoring
business
medicine.drug
Zdroj: Clinical and Applied Thrombosis/Hemostasis, Vol 27 (2021)
Clinical and Applied Thrombosis/Hemostasis
ISSN: 1938-2723
Popis: A rapid and reliable assessment of the dabigatran effect is desirable in dabigatran treated patients with uncontrolled bleeding or before acute surgery. The aim of this study was to study the anticoagulant effects of dabigatran in patients with atrial fibrillation (AF) as assessed by the whole blood assays ROTEM, and how data from these methods correlate to plasma dabigatran concentrations measured by Hemoclot. ROTEM was performed with ROTEM Gamma (Pentapharm GmbH, Munich, Germany). The assays used in our study were Ex-tem and In-tem assay. Plasma dabigatran concentrations were determined by hemoclot thrombin inhibitor assay (Hyphen BioMed, France) at trough and post-dose in 27 patients on dabigatran 150 mg BID. Median plasma dabigatran concentrations at trough were 74 ng/mL (11.2–250) and post-dose (2 h after ingestion) 120 ng/mL (31–282). The ROTEM clotting time (CT) and maximum clot firmnes (MCF) correlated strongly with dabigatran concentrations when activated with the reagents Ex-tem (p < 0.0001) and In-tem (p < 0.0001). In summary, in our study, we have found that the ROTEM variable CT and MCF, when activated with triggers Ex-tem and In-tem, has a strong and highly significant correlation with the plasma dabigatran concentration in a real-life population of AF-patients and could thereby be an alternative to estimate dabigatran concentration in emergency situations. However, additional studies are needed to further validate these findings.
Databáze: OpenAIRE
Externí odkaz: